Advertisement

Topics

Latest "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Stories - Page: 5

10:48 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Achillion Reports Preliminary Proof Concept With 4471 Treatment" found in our extensive news archives from over 250 global news sources.

More Information about Achillion Reports Preliminary Proof Concept With 4471 Treatment on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Achillion Reports Preliminary Proof Concept With 4471 Treatment for you to read. Along with our medical data and news we also list Achillion Reports Preliminary Proof Concept With 4471 Treatment Clinical Trials, which are updated daily. BioPortfolio also has a large database of Achillion Reports Preliminary Proof Concept With 4471 Treatment Companies for you to search.

Showing "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Articles 101–125 of 22,000+

Monday 18th March 2019

Biohaven Secures a Priority Review Voucher for its Rimegepant Zydis for Treatment of Migraine

NEW HAVEN, Conn., March 18, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the company has purchased a U.S. Food and Drug Administration (FDA...


HAEMATO AG: Preliminary Results 2018

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results 18.03.2019 / 15:14 The issuer is solely responsible for the content of this announcement. Corporate News of HAEMATO AG: HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 27...

Patience and Planning: Mary Jane Minkin, MD of MadameOvary Weighs in on Lifestyle Tips for Couples Trying to Conceive

An increasing number of studies are emphasizing the importance of lifestyle changes when trying to conceive. The latest, as determined by researchers from Washington University in St. Louis, reports that going to bed on time and getting enough sleep may reduce the time it takes to become pregnant. “For many


News & Views: A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells from people with cystic fibrosis and an animal model of the disease, reports a Nature paper. https://go.nature.com/2UDN0kW 

News & Views: A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells from people with cystic fibrosis and an animal model of the disease, reports a Nature paper. https://go.nature.com/2UDN0kW 

Dermira Shares Soar After Eczema Drug Hits Goal of Mid-Stage Study

An experimental drug developed by Dermira to treat atopic dermatitis has hit the main goal of its mid-stage study, helping to build a case that the injectable treatment could measure up against a drug from Regeneron Pharmaceuticals and Sanofi. Atopic dermatitis is the most common and severe form of eczema, an inflammatory condition that leads […]

AssuredLeads Launches SaaS Platform

Platform will produce exclusive leads in commercial insurance industry MADISON, Wis. (PRWEB) March 18, 2019 To help commercial insurance agents increase sales production without increasing underwriting expenses, AssuredLeads has launched its SaaS platform, which is designed to assist in every step of the commercial insurance sales process from the agent and broker, to the carrier level. “Havin...

Catheter ablation for atrial fibrillation no better than drug therapy for reducing death or disabling stroke, trial finds

Catheter ablation achieved no significant reduction in death, disabling stroke, serious bleeding, or cardiac arrest compared with drug treatment in patients with atrial fibrillation (AF) in a large...

Third of patients with lower GI cancers face delays

A third of patients in England with lower gastrointestinal cancers are facing delayed treatment, while figures show that NHS performance against treatment time targets has fallen to an all time...

Medication Treatment of Delirium: How Far Have We Come?

A sophisticated analysis suggests two useful interventions, but clinicians should consider simple environmental interventions before adding yet another medication.

Daré Bioscience's stock more than doubles after positive findings for Tamoxifen from VVA treatment study

It could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in breast cancer patients

MIT researchers devise new way to reduce burden of tuberculosis treatment

MIT said about one third of world’s population is affected by the deadly infectious disease and one of the main reasons TB is so pervasive is that the The post MIT researchers devise new way to reduce burden of tuberculosis treatment appeared first on Compelo Medical Devices - Latest industry news and analysis.

Tonix cites initiation of Phase 3 trial for post-traumatic stress disorder drug

The clinical-stage biopharmaceutical company said enrollment began in March for the study of Tonmya for the treatment of post-traumatic stress disorder

CDC Cites Urgent Need to Expand HIV Testing, Treatment

MONDAY, March 18, 2019 -- Shortfalls in HIV testing and treatment are hampering efforts to stop new infections of the AIDS-causing virus in the United States, the Centers for Disease Control and Prevention says. "We have the tools to end the HIV...

Karuna Snags $68 Million to Support Schizophrenia Treatment Development http://dlvr.it/R13Xx6 pic.twitter.com/QvZqXPKjo9

Karuna Snags $68 Million to Support Schizophrenia Treatment Development http://dlvr.it/R13Xx6  pic.twitter.com/QvZqXPKjo9

Edison initiates coverage on Actinogen Medical (ACW)

Edison Investment Research Limited 18-March-2019 / 12:33 GMT/BST London, UK, 18 March 2019 Edison initiates coverage on Actinogen Medical (ACW) Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem(R) is a selective 11β-HSD1 inhibitor that is able to cross the bloo...

For Recent-Onset Afib, Delayed Cardioversion Noninferior to Early Treatment

(MedPage Today) -- Wait-and-see strategy outcomes similar in study

Healthy fats improve nerve function in obese mice

Swapping dietary saturated fats for monounsaturated fats reverses nerve damage and restores nerve function in male mice, finds new preclinical research. These data support further investigation of diets rich in healthy fats as a potential treatment for the nerve damage that occurs with diabetes, known as diabetic neuropathy.

Common treatment for multiple sclerosis may prolong life

Researchers have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients.

Early Switch to Oral Treatment of Endocarditis: No Delayed Treatment Failure

Switching from intravenous to early oral treatment in stable patients was not associated with delayed treatment failure during 3.5 years of follow-up.

STAT Plus: Regeneron's Dupixent is a commercial blockbuster. Now the small biotech Dermira could challenge that dominance in eczema treatment. https://buff.ly/2UIFLYH 

STAT Plus: Regeneron's Dupixent is a commercial blockbuster. Now the small biotech Dermira could challenge that dominance in eczema treatment. https://buff.ly/2UIFLYH 

3Bar Biologics and Pivot Bio Help Farmers Increase Crop Productivity and Decrease Need for Fertilizer

Unique Delivery System Ensures Quality Product COLUMBUS, Ohio and BERKELEY, Calif. (PRWEB) March 18, 2019 3Bar Biologics, the cutting-edge biotech company and Pivot Bio, the leader in microbial solutions announce today they have entered into an agreement for 3Bar to provide a proprietary delivery system for Pivot Bio PROVENTM, Pivot Bio’s breakthrough product for biologic nitrogen fixation for ...

LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald. “Trui brings incredible expertise to ...

3M Announces New Business Segments and Leadership Appointments

New Structure Increases Customer Focus, Agility and Productivity 3M today announced the realignment of the company from five to four business segments. The new alignment will enable the company to better serve global customers and markets. “We are continuing to advance 3M into the future, and today’s actions will strengthen our ability to ...

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

- License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration. - OliX to receive an upfront payment of 2 million euro, and eligible to receive milestones, plus royalty for the development and commercialization in

Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved indication resulted in a 34% reduction in the risk of invasive disease recurrence or death ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks